News
Filter
-
LifeArc appoints new General Counsel and Company Secretary and Chief Communications Officer
-
LifeArc supports research to develop a quick, affordable blood test for the early detection of dementia
-
LifeArc joins transatlantic collaboration to develop a treatment for Crimean-Congo Hemorrhagic Fever
-
LifeArc joins the REMEDi4ALL Consortium, a pioneering global platform shaping the future of drug repurposing
-
£1 million partnership aims to develop new treatments for congenital muscular dystrophy
-
Tribune Therapeutics raises EUR 37 million for next-generation anti-fibrotic therapies
-
Hillstar Bio closes $67 million Series A financing round
-
LifeArc invests in Maxion Therapeutics Series A
-
Reflecting on our commitment to involve patients and the public in our work
-
Reflections from the LifeArc Translational Science Summit on MND and Rare Dementias
-
LifeArc Ventures 2024: new investments, targeted follow-ons and substantive portfolio progress
-
LifeArc and Neuropeutics Inc join forces to advance a new treatment for MND/ALS
